Bausch + Lomb Showcases Data, Signals Ophthalmology Strategy Shift
Event summary
- Bausch + Lomb will present 45 scientific data presentations and posters at the ASCRS annual meeting in Washington, D.C., April 10-13, 2026.
- The presentations will focus on Bausch + Lomb's portfolio, including ELIOS MIGS, enVista IOLs, MIEBO, ScoutPro, Stellaris Elite, TENEO laser platform, and XIIDRA.
- The company is hosting events including a session on ophthalmology strategics and a debate on the future of communication in ophthalmology.
- The press release highlights real-world data and patient outcomes across multiple product lines, suggesting a focus on demonstrating clinical value.
The big picture
Bausch + Lomb’s presentation at ASCRS signals a move beyond product promotion to a data-driven approach, emphasizing real-world evidence to bolster its market position. The inclusion of a session on ophthalmology strategics indicates a heightened awareness of industry consolidation and competitive pressures. This focus on clinical data and strategic positioning is crucial for maintaining market share in the increasingly competitive global eye health market, which is projected to reach $45 billion by 2030.
What we're watching
- Market Positioning
- Bausch + Lomb's emphasis on real-world data suggests a strategic shift towards demonstrating clinical efficacy and value to differentiate from competitors in a crowded market.
- Regulatory Scrutiny
- Increased focus on patient-reported outcomes and safety data may reflect heightened regulatory scrutiny and a need to proactively address potential concerns.
- Competitive Landscape
- The discussions around ophthalmology strategics and communication suggest Bausch + Lomb is actively monitoring and responding to evolving competitive dynamics within the eye care market.
Related topics